Study of SCY-635, Pegasys and Copegus in Hepatitis C



Status:Archived
Conditions:Hepatitis
Therapuetic Areas:Immunology / Infectious Diseases
Healthy:No
Age Range:Any
Updated:7/1/2011
Start Date:November 2010

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

A Phase 2a Study of SCY-635 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naive Subjects With Genotype 1 Hepatitis C Infection


This study will examine the effectiveness of 28 days of triple combination therapy including
SCY-635 with peginterferon alfa 2a and ribavirin in reducing serum HCV RNA levels. An
additional 44 weeks of treatment with the currently approved standard of care will be
offered to all participants.



We found this trial at
4
sites
University of North Carolina Hospital
Chapel Hill, North Carolina 27599
?
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Duke Univ Med Ctr
2301 Erwin Rd
Durham, North Carolina 27710
919-684-8111
Duke Univ Med Ctr As a world-class academic and health care system, Duke Medicine strives...
?
mi
from
Durham, NC
Click here to add this to my saved trials
Alamo Medical Research
San Antonio, Texas 78215
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
Quest Clinical Research
San Francisco, California 94115
?
mi
from
San Francisco, CA
Click here to add this to my saved trials